The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of pemetrexed-carboplatin and gemcitabine-vinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer.
D. Amadori
No relevant relationships to disclose
I. La Torre
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
E. M. Carrasco
Stock Ownership - Lilly
Research Funding - Lilly (I)
S. Roesel
No relevant relationships to disclose
R. Labianca
No relevant relationships to disclose
V. Moreau-Donnet
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. Desaiah
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. Martin
No relevant relationships to disclose